Shares of Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $5.12.
GUTS has been the subject of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Thursday, June 4th. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Craig Hallum started coverage on shares of Fractyl Health in a report on Wednesday. They issued a “buy” rating and a $4.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th.
Read Our Latest Research Report on Fractyl Health
Fractyl Health Price Performance
Fractyl Health (NASDAQ:GUTS – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.23. Research analysts predict that Fractyl Health will post -0.6 EPS for the current fiscal year.
Insider Activity
In other Fractyl Health news, Director William Bradley bought 68,493 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the purchase, the director owned 84,622 shares in the company, valued at $61,774.06. This represents a 424.66% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ian Sheffield purchased 35,000 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the acquisition, the director owned 35,000 shares of the company’s stock, valued at approximately $25,550. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 171,493 shares of company stock valued at $127,150. 8.52% of the stock is owned by insiders.
Hedge Funds Weigh In On Fractyl Health
Several hedge funds have recently bought and sold shares of the business. FNY Investment Advisers LLC bought a new position in Fractyl Health in the 3rd quarter valued at $31,000. Jane Street Group LLC purchased a new stake in shares of Fractyl Health during the second quarter valued at $31,000. Accredited Investors Inc. purchased a new stake in shares of Fractyl Health during the first quarter valued at $46,000. Scientech Research LLC bought a new position in shares of Fractyl Health in the third quarter worth about $49,000. Finally, Prelude Capital Management LLC bought a new position in shares of Fractyl Health in the third quarter worth about $55,000.
Fractyl Health Company Profile
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Read More
- Five stocks we like better than Fractyl Health
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
